Diltiazem hydrochloride sustained release pharmaceutical and use thereof
Abstract
Abstract PURPOSE:To obtain the titled pharmaceutical useful as a remedy for angina pectoris, etc. industrially and advantageously, by adding an acrylic acid resin as a sustained releasing agent in a specific proportion in the form of a solution or dispersion to mixed powder of diltiazem hydrochloride and an excipient and granulating the resultant mixture. CONSTITUTION:An acrylic acid resin, e.g. a copolymer of methyl methacrylate and methacrylic acid, etc., as a sustained releasing agent in an amount of about 5-20% based on the weight of the aimed pharmaceutical is incorporated in diltiazem hydrochloride to afford the titled pharmaceutical. Specifically, diltiazem is incorporated with an excipient, preferably lactose, and an acrylic acid resin solution or dispersion is added to granulate the resultant mixture. The resultant granulated material can be dried, mixed with a lubricant and molded to afford industrially and advantageously the pharmaceutical. The addition of a small amount of the acrylic acid resin permits effective sustained release of the diltiazem hydrochloride and the effective concentration in blood can be maintained for a long period.
Inventors
- 👤 Yasumasa Nakamoto
- 👤 中本 泰正
- 👤 Yoriyasu Ishizuka
- 👤 石塚 仍康
- 👤 Tsurayama Ogawa
- 👤 小川 貫山
- 👤 Toru Ishise
- 👤 石瀬 徹
Bibliographic Details
Claims Analysis
Total Claims: 0References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.